Ambroxol

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Mucolytic, expectorant. Significance in dermatology, especially in the context of drug exanthema.

Half-lifeThis section has been translated automatically.

3,5–4 h

Pharmacodynamics (Effect)This section has been translated automatically.

Metabolite of bromhexine, secretolytic, stimulation of surfactant synthesis in type II pneumocytes, antioxidant.

IndicationThis section has been translated automatically.

Expectoration promotion in bronchial asthma, chronic bronchitis, cough.

Limited indicationThis section has been translated automatically.

Pregnancy 1st trimester, lactation, epilepsy, renal failure.

Dosage and method of useThis section has been translated automatically.

  • In the first 2-3 days of treatment 30 mg p.o. 3 times/day, then 30 mg twice/day or 15 mg 3 times/day.
  • 1-2 times/day 2-3 ml of the 0.75% solution per inhalation
  • 2-3 times/day 15-30 mg i.v., s.c. or i.m.

Undesirable effectsThis section has been translated automatically.

Allergic reactions up to anaphylactic shock, headache, seizures, facial edema, dyspnoea, laryngeal edema, gastrointestinal disorders, arthralgias.

InteractionsThis section has been translated automatically.

No simultaneous administration of antitussives, as there is a risk of secretion congestion.

ContraindicationThis section has been translated automatically.

Paragroup allergy (for some liquid preparations), bronchial asthma: for sulphite-containing preparations

PreparationsThis section has been translated automatically.

Ambroxol, Bronchopront, Mucosolvan, Pediamuc

PatientinformationThis section has been translated automatically.

Patients should drink a lot, as this is the basic condition for an expectorant stimulating effect!

Authors

Last updated on: 29.10.2020